Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Caribou Biosciences, Inc. securities between July 14, 2023 and ...

Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the therapy itself caused any type of secondary cancer in the modified T cells, ...

Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the ...

The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene Therapeutics’ ALLO-329, an investigational allogenic CAR-T cell therapy.

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

A new advance may make it possible to use off-the-shelf CAR T cells provided by healthy donors. The new approach studied in mice equipped CAR T cells with the viral protein Nef.

If you purchased or acquired securities in Caribou between July 14, 2023 and July 16, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...

CARGO Therapeutics, Inc. (NASDAQ: CRGX) recently disclosed key updates regarding its strategic direction, workforce, and financial impacts. The company’s Board of Directors greenlit a decision to ...

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune T cells and engineering them to recognize specific targets ...

Patients with colon cancer who still have cancer cells in their blood after surgery may improve their survival odds with ...